Global Human Gene Therapy Market Growth 2025-2031

The global Human Gene Therapy market size is predicted to grow from US$ 5868 million in 2025 to US$ 8579 million in 2031; it is expected to grow at a CAGR of 6.5% from 2025 to 2031.

Gene therapy is a medical approach that treats or prevents disease by correcting the underlying genetic problem. Gene therapy techniques allow doctors to treat a disorder by altering a person"s genetic makeup instead of using drugs or surgery.

Advances in gene therapy technology, increasing understanding of genetics, and the potential for addressing previously untreatable diseases contribute to the growth of the Human Gene Therapy market.

LP Information, Inc. (LPI) ' newest research report, the “Human Gene Therapy Industry Forecast” looks at past sales and reviews total world Human Gene Therapy sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Gene Therapy sales for 2025 through 2031. With Human Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Human Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Gene Therapy.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Gene Therapy market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Non-viral Vectors
Viral Vectors

Segmentation by Application:
Neurological Diseases
Cancer
DMD (Duchenne Muscular Dystrophy)
Hepatological Diseases
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Biogen
Sarepta Therapeutics
Gilead Sciences
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Human Stem Cells Institute
Sibiono Genetech
Shanghai Sunway Biotech
Uniqure N.V.
Gensight Biologics S.A.
Celgene Corporation
Cellectis
Sangamo Therapeutics
Mustang Bio
AGTC
Poseida Therapeutics

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Gene Therapy market?

What factors are driving Human Gene Therapy market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Gene Therapy market opportunities vary by end market size?

How does Human Gene Therapy break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.